Glutathione S-conjugation of the sevoflurane degradation product, fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (Compound A) in human liver, kidney, and blood in vitro

Toxicology and Applied Pharmacology

Volumn 177, Issue 2, 2001, Pages 85-93

  Altuntas, T Gul ^a   Kharasch, Evan D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,2 DIFLUORO 1 (TRIFLUOROMETHYL)VINYL FLUOROMETHYL ETHER; CYSTEINE CONJUGATE; GLUTATHIONE; GLUTATHIONE DERIVATIVE; LYASE; SEVOFLURANE; THIOL DERIVATIVE;

ARTICLE; BLOOD; CELL FRACTIONATION; CYTOSOLIC FRACTION; DRUG DEGRADATION; GLUTATHIONE METABOLISM; HUMAN; IN VITRO STUDY; KIDNEY METABOLISM; KIDNEY MICROSOME; LIQUID CHROMATOGRAPHY; LIVER METABOLISM; LIVER MICROSOME; MASS SPECTROMETRY; NEPHROTOXICITY;

EID: 0035671491     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.2001.9302     Document Type: Article

References (37)

1. Biotransformation of trichloroethene. Dose dependent excretion of 2,2,2-trichlorometabolites and mercapturic acids in rats and humans after inhalation
2. N-acetyl-S-(1,2,2-trichlorovinyl)-L-cysteine and 2,2,2-trichloroethanol. Two novel metabolites of tetrachloroethene in humans after occupational exposure
3. Nephrotoxic and genotoxic N-acetyl-S-dichlorovinyl-L-cysteine is a urinary metabolite after occupational 1,1,2-trichloroethene exposure in humans: Implications for the risk of trichloroethene exposure
4. Effects of low-flow sevoflurane anesthesia on renal function: Comparison with high-flow sevoflurane anesthesia and low-flow isoflurane anesthesia
5. Acute intoxication with trichloroethene: Clinical symptoms, toxicokinetics, metabolism, and development of biochemical parameters for renal damage
6. Metabolism and toxicity of trichloroethylene and S-(1,2-dichlorovinyl)-L-cysteine in freshly isolated human proximal tubular cells
7. Bioactivation mechanism of the cytotoxic and nephrotoxic S-conjugate S-(2-chloro-1,1,2-trifluoroethyl)-L-cysteine
8. Thioketene formation from α-haloalkenyl 2-nitrophenyl disulfides: Models for biological reactive intermediates of cytotoxic S-conjugates
9. 2 absorbants during low-flow anesthesia in surgical patients
10. Toxicity of compound A in rats: Effect of a 3-hour administration
11. Toxicity of compound A in rats: Effect of increasing duration of administration
12. The role of glutathione conjugation in the development of kidney tumors in rats exposed to trichloroethylene
13. Perchloroethylene-induced rat kidney tumors: An investigation of the mechanisms involved and their relevance to humans
14. Decomposition of sevoflurane by soda lime
15. Cysteine conjugate β-lyase-dependent biotransformation of the cysteine S-conjugates of the sevoflurane degradation product compound A in human, nonhuman primate, and rat kidney cytosol and mithochondria
16. Cysteine conjugate β-lyase-dependent biotransformation of the cysteine S-conjugates of the sevoflurane degradation product 2-(fluoromethoxy)-1,1,3,3,3-pentafluoro-1-propene (compound A)
17. Nephrotoxicity of the glutathione and cysteine S-conjugates of the sevoflurane degradation product 2-(fluoromethoxy)-1,1,3,3,3-pentafluoro-1-propene (compound A) in male Fisher 344 rats
18. Cysteine conjugate β-lyase dependent metabolism of compound A (2-[fluoromethoxy]-1,1,3,3,3-pentafluoro-1-propene) in human subjects anesthetized with sevoflurane and in rats given compound A
19. Nephrotoxicity of sevoflurane compound A (fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether in rats: Evidence for glutathione and cysteine conjugate formation and the role of renal cysteine conjugate β-lyase
20. Identification in rat bile of glutathione conjugates of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether, a nephrotoxic degradate of the anesthetic agent of sevoflurane
21. Inhalation toxicity of a haloalkene degredant of sevoflurane, compound A (PIFE), in Sprague-Dawley rats
22. Role of renal cysteine conjugate β-lyase in inhaled compound A nephrotoxicity in rats
23. Compound A uptake and metabolism to mercapturic acids and 3,3,3-trifluoro-2-fluoromethoxypropanoic acid during low-flow sevoflurane anesthesia
24. Dose-dependent metabolism of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), an anesthetic degradation product, to mercapturic acids and 3,3,3-trifluoro-2-(fluoromethoxy)propanoic acid in rats
25. Role of renal cysteine conjugate β-lyase in the mechanism of compound A nephrotoxicity in rats
26. Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane and methoxyflurane
27. Purification and characterization of human kidney cytosolic cysteine conjugate β-lyase activity
28. Distribution of oxidized and reduced forms of glutathione and cysteine in rat plasma
29. Glutathione conjugation of trichloroethylene in human liver and kidney: Kinetics and individual variation
30. Identification of S-(1,2-dichlorovinyl)glutathione in the blood of human volunteers exposed to trichloroethylene
31. Protein measurement with folin phenol reagent
32. Reaction of sevoflurane and its degradation products with soda lime: Toxicity of the byproducts
33. The effects of prolonged low-flow sevoflurane anesthesia on renal and hepatic function
34. Dose-dependent protein adduct formation in kidney, liver and blood of rats and human blood after perchloroethene inhalation
35. HPLC with o-phthalaldehyde precolumn derivatization to measure total, oxidized, and protein-bound glutathione in blood, plasma, and tissue
36. Evidence for metabolism of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product, by cysteine conjugate β-lyase
37. Biotransformation of perchloroethene, dose-dependent excretion of trichloroacetic acid, dichloroacetic acid, and N-acetyl-S-(trichlorovinyl)-L-cysteine in rats and humans after inhalation